A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci (Pneucast)

March 20, 2019 updated by: Public Health England
A study taking swabs from the back of the nose (nasopharynx) to look at carriage of pneumococci.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Gloucester, United Kingdom
        • Health Protection Agency
      • London, United Kingdom, NW9 5HT
        • Health Protection Agency
    • Hertfordshire
      • Stevenage, Hertfordshire, United Kingdom
        • Health Protection Agency

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Community samples taken within the home of eligible subjects.

Description

Inclusion Criteria:

  • Born in a cohort eligible for routine or catch up pneumococcal conjugate vaccination (i.e. date of birth since 4th September 2004) or a family member where a child is eligible and has been enrolled
  • Written informed consent given by the subject's parent/ legal guardian as well as assent from the child after the nature of the study has been explained to them or
  • Written informed consent given by the subject after the nature of the study has been explained to them

Exclusion Criteria:

  • Moderate to severe disability.
  • Cerebral palsy, syndromes and neurological disorders affecting swallowing.
  • Ear Nose and Throat disorders affecting the anatomy of the ear,i.e.malformed ears.
  • Confirmed or suspected immunodeficiency (congenital or acquired).
  • On immunosuppressive therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Presence of pneumococci in nasopharyngeal swabs

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Public Health England

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Primary Completion (Actual)

March 1, 2010

Study Completion (Actual)

March 1, 2010

Study Registration Dates

First Submitted

December 28, 2009

First Submitted That Met QC Criteria

December 28, 2009

First Posted (Estimate)

December 29, 2009

Study Record Updates

Last Update Posted (Actual)

March 22, 2019

Last Update Submitted That Met QC Criteria

March 20, 2019

Last Verified

September 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PneuCaSt

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumococcal Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe